X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218599
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216877
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-12-2022-83607.pdf
https://www.globenewswire.com/news-release/2022/07/20/2482362/0/en/Hyloris-Reports-Positive-Phase-1-Data-for-HY-004-a-proprietary-Tranexamic-Acid-Oral-Mouth-Rinse-for-bleeding-related-to-dental-procedures.html
https://amilifesciences.com/left_service/ami-lifesciences-first-generic-company-to-receive-dcgi-approval-for-obeticholic-acid/
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003601
https://www.empr.com/home/news/safety-alerts-and-recalls/fda-risk-of-inadvertent-intrathecal-administration-of-tranexamic-acid-injection/#:~:text=by%20intravenous%20route.-,The%20FDA%20notes%20that%20the%20inadvertent%20intrathecal%20administration%20of%20tranexamic,permanent%20neurological%20injury%2C%20and%20death.
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-9-2020-1600260117.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-initiates-voluntary-nationwide-recall-four-lots-amiodarone-hcl-injection-usp-and-tranexamic#:~:text=Mylan%20N.V.%20(NASDAQ%3A%20MYL),Injection%2C%20USP%201000%20mg%2F10
https://www.prnewswire.com/news-releases/mylan-initiates-voluntary-nationwide-recall-of-four-lots-of-amiodarone-hcl-injection-usp-and-tranexamic-acid-injection-usp-due-to-carton-label-mix-up-301120584.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209860
https://www.business-standard.com/article/companies/strides-bengaluru-unit-gets-voluntary-indicated-action-status-from-usfda-119072000190_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212360
https://www.pharmacompass.com/pdf/news/erfa-canada-2012-recalls-erfa-tranexamic-100-mgml-5-ml-1525761805.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206594
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205228
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206713
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208840
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207239
https://www.pharmacompass.com/pdf/news/amerigen-pharms-antifibrinolytic-generic-drug-tranexamic-acid-approved-in-usa-1469863341.pdf
https://www.pharmacompass.com/pdf/news/north-creeks-generic-tranexamic-acid-approved-in-us-to-reduce-heavy-bleeding-1456829577.pdf
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-gets-usfda-nod-for-two-generic-drugs/articleshow/50604765.cms
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
Market Place
Share 
